Skip navigation

Dow Chemical to bring 800 workers to Pa. R&D site

Dow Chemical Co. is moving 800 workers by the end of next year to a new research-and-development facility on a sprawling campus that is also home to drug giant Pfizer Inc.Full story

NH expects share of Pfizer drug settlement

New Hampshire is expected to get more than $168,000 as part of a national settlement with drugmaker Pfizer Inc. Full story

Pfizer to return $700,000 to Okla. health care

Pfizer Inc. has agreed to pay almost $491 million to settle allegations it illegally marketed an organ transplant drug and will return more than $27 million to state health care programs, including about $700,000 to Oklahoma, a prosecutor said Tuesday. Full story

Sponsored Links

Articles

News Summary: Pfizer 2Q profit beats, sales fall

Pfizer to pay $491M to resolve drug marketing case

Cost controls help Pfizer, Merck weather weak quarter

Pfizer settles U.S. marketing case dating to Wyeth conduct

News Summary: Pfizer sells key vaccine cheaply

Pfizer to split generic, branded drugs units

Pfizer will reorganize commercial operations

Earnings Preview: Pfizer to report on new drugs

Exclusive: Pfizer not moving forward with Onyx bid: sources

European regulators expand Pfizer vaccine approval

Video

  Lower-cost Lipitor alternatives may come soon

The cholesterol-lowering drug Lipitor has generated $106 billion for its manufacturer Pfizer over the past decade. But at the end of this month, Pfizer's patent expires and lower cost generic alternatives will go on the market. NBC’s Robert Bazell has more.

advertisement | ad info

Related Photos

People walk past the Pfizer Inc. headquarters in New York, January 31, 2013.
People walk past the Pfizer Inc. headquarters in New York, January 31, 2013.

People walk past the Pfizer Inc. headquarters in New York, January 31, 2013. REUTERS/Brendan McDermid

People walk past the Pfizer Inc. headquarters in New York in this file photo
People walk past the Pfizer Inc. headquarters in New York in this file photo

People walk past the Pfizer Inc. headquarters in New York, in this file photo from January 31, 2013. Pfizer Inc reported second-quarter earnings slightly ahead of estimates July 30, 2013 as the largest U.S. drugmaker lines up a business split that could lead to the spinoff of its generics division.

Jansen, senior vice president of Vaccine Research and Early Development at Pfizer Inc, poses in her lab at Pfizer headquarters in Pearl River
Jansen, senior vice president of Vaccine Research and Early Development at Pfizer Inc, poses in her lab at Pfizer headquarters in Pearl River

Kathrin Jansen, senior vice president of Vaccine Research and Early Development at Pfizer Inc, poses for a portrait in one of her labs at Pfizer headquarters in Pearl River, New York, April 19, 2013. REUTERS/Carlo Allegri